Fixed- versus variable-dose prothrombin complex concentrate protocol for vitamin K antagonist reversal

Area of Science:

• Pharmacology and Therapeutics
• Hematology
• Critical Care Medicine

Background:

• Fixed-dose prothrombin complex concentrates (PCCs) are used to reverse vitamin K antagonists, potentially reducing thromboembolic events, costs, and delays.
• The optimal fixed dose remains uncertain, with some evidence suggesting inadequate reversal in patients with high International Normalized Ratio (INR) or weight.
• A modified fixed-dose strategy considering patient weight and INR may be necessary.

Purpose of the Study:

• To compare the efficacy and safety of a standard variable-dose protocol versus a fixed-dose protocol for PCC administration.
• To evaluate the proportion of patients achieving INR reversal and assess treatment costs.

Main Methods:

• Retrospective chart review of 113 patients.
• Comparison of outcomes between a standard variable-dose PCC protocol and a fixed-dose PCC protocol.
• Primary outcome: proportion of patients achieving INR reversal (INR < 1.5 or INR ≤ 1.3 for ICH patients).

Main Results:

• No significant difference in INR reversal rates between variable-dose (46%) and fixed-dose (43%) groups (P=0.83).
• For patients with intracranial hemorrhage (ICH), INR reversal rates were 71% for variable-dose and 50% for fixed-dose (P=0.41).
• The fixed-dose group utilized less PCC and incurred lower treatment costs.

Conclusions:

• The fixed-dose PCC protocol did not significantly differ in INR reversal efficacy compared to the variable-dose protocol.
• Fixed-dose PCC administration resulted in reduced PCC usage and lower treatment costs.
• Further research may be needed to optimize fixed-dose strategies considering patient-specific factors like INR and weight.